<b><i>Business Combinations</i></b><p style="margin-top:0px;margin-bottom:-6px"><font size="1"></font></p><p style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">We allocate the purchase price of acquired businesses to the tangible and intangible assets acquired and
liabilities assumed based upon their estimated fair values on the acquisition date. The purchase price allocation process requires management to make significant estimates and assumptions, especially at the acquisition date with respect to
intangible assets and in-process research and development (IPR&amp;D). In connection with the purchase price allocations for acquisitions, we estimate the fair value of contingent consideration payments utilizing a probability-based income approach
inclusive of an estimated discount rate.</font></p><p style="margin-top:0px;margin-bottom:0px"><font size="1"></font></p><p style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">Although
we believe the assumptions and estimates made are reasonable, they are based in part on historical experience and information obtained from the management of the acquired businesses and are inherently uncertain. Examples of critical estimates in
valuing certain of the intangible assets and any contingent consideration we have acquired or may acquire in the future include but are not limited to:</font></p><p style="margin-top:0px;margin-bottom:-6px"><font size="1"></font></p><table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE" width="100%">
<tr>
<td width="4%"><font size="1"></font></td>
<td align="left" valign="top" width="2%"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="top" width="1%"></td>
<td align="left" valign="top"> <p align="left"><font size="2" style="font-family:Times New Roman">the feasibility and timing of achievement of development, regulatory and commercial milestones;</font></p></td></tr></table><tr>
<td width="4%"><font size="1"></font></td>
<td align="left" valign="top" width="2%"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="top" width="1%"></td>
<td align="left" valign="top"> <p align="left"><font size="2" style="font-family:Times New Roman">the feasibility and timing of achievement of development, regulatory and commercial milestones;</font></p></td></tr><td width="4%"><font size="1"></font></td><td align="left" valign="top" width="2%"><font size="2" style="font-family:Times New Roman"></font></td><td valign="top" width="1%"></td><td align="left" valign="top"> <p align="left"><font size="2" style="font-family:Times New Roman">the feasibility and timing of achievement of development, regulatory and commercial milestones;</font></p></td><p align="left"><font size="2" style="font-family:Times New Roman">the feasibility and timing of achievement of development, regulatory and commercial milestones;</font></p><p style="margin-top:0px;margin-bottom:-6px"><font size="1"></font></p><table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE" width="100%">
<tr>
<td width="4%"><font size="1"></font></td>
<td align="left" valign="top" width="2%"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="top" width="1%"></td>
<td align="left" valign="top"> <p align="left"><font size="2" style="font-family:Times New Roman">expected costs to develop the in-process research and development into commercially viable products; and</font></p></td></tr></table><tr>
<td width="4%"><font size="1"></font></td>
<td align="left" valign="top" width="2%"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="top" width="1%"></td>
<td align="left" valign="top"> <p align="left"><font size="2" style="font-family:Times New Roman">expected costs to develop the in-process research and development into commercially viable products; and</font></p></td></tr><td width="4%"><font size="1"></font></td><td align="left" valign="top" width="2%"><font size="2" style="font-family:Times New Roman"></font></td><td valign="top" width="1%"></td><td align="left" valign="top"> <p align="left"><font size="2" style="font-family:Times New Roman">expected costs to develop the in-process research and development into commercially viable products; and</font></p></td><p align="left"><font size="2" style="font-family:Times New Roman">expected costs to develop the in-process research and development into commercially viable products; and</font></p><p style="margin-top:0px;margin-bottom:-6px"><font size="1"></font></p><table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE" width="100%">
<tr>
<td width="4%"><font size="1"></font></td>
<td align="left" valign="top" width="2%"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="top" width="1%"></td>
<td align="left" valign="top"> <p align="left"><font size="2" style="font-family:Times New Roman">future expected cash flows from product sales. </font></p></td></tr></table><tr>
<td width="4%"><font size="1"></font></td>
<td align="left" valign="top" width="2%"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="top" width="1%"></td>
<td align="left" valign="top"> <p align="left"><font size="2" style="font-family:Times New Roman">future expected cash flows from product sales. </font></p></td></tr><td width="4%"><font size="1"></font></td><td align="left" valign="top" width="2%"><font size="2" style="font-family:Times New Roman"></font></td><td valign="top" width="1%"></td><td align="left" valign="top"> <p align="left"><font size="2" style="font-family:Times New Roman">future expected cash flows from product sales. </font></p></td><p align="left"><font size="2" style="font-family:Times New Roman">future expected cash flows from product sales. </font></p><p style="margin-top:0px;margin-bottom:0px"><font size="1"></font></p><p style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">Unanticipated events and circumstances may occur which may
affect the accuracy or validity of such assumptions, estimates or actual results. </font></p><p style="margin-top:0px;margin-bottom:0px"><font size="1"></font></p><p style="margin-top:0px;margin-bottom:0px; margin-left:2%"><font size="2" style="font-family:Times New Roman"><b><i>Valuation of Contingent Acquisition Consideration Payable </i></b></font></p><p style="margin-top:0px;margin-bottom:-6px"><font size="1"></font></p><p style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">Each period we reassess the fair value of the contingent acquisition consideration payable associated with certain acquisitions and record
increases in the fair value as contingent consideration expense and record decreases in the fair value as a reduction of contingent consideration expense. Increases or decreases in the fair value of the contingent acquisition consideration payable
can result from changes in assumed probability adjustments with respect to regulatory approval, changes in the assumed timing of when milestones will be achieved and changes in assumed discount periods and rates. Significant judgment is employed in
determining the appropriateness of these assumptions each period. Accordingly, future business and economic conditions, as well as changes in any of the assumptions described in the accounting for business combinations above can materially impact
the amount of contingent consideration expense that we record in any given period. </font></p><p style="margin-top:0px;margin-bottom:0px"><font size="1"></font></p><p style="margin-top:0px;margin-bottom:0px; margin-left:2%"><font size="2" style="font-family:Times New Roman"><b><i>Income Taxes </i></b></font></p><p style="margin-top:0px;margin-bottom:-6px"><font size="1"></font></p><p style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">Our consolidated balance sheets reflect net deferred tax assets that primarily represent the tax benefit of net operating loss carryforwards and credits and timing differences between book and tax
recognition of certain revenue and expense items, net of a valuation allowance. When it is more likely than not that all or some portion of deferred tax assets may not be realized, we establish a valuation allowance for the amount that may not be
realized. Each quarter, we evaluate the need to retain all or a portion of the valuation allowance on our net deferred tax assets. Our evaluation considers historical earnings, estimated future taxable income and ongoing prudent and feasible tax
planning strategies. Adjustments to the valuation allowance increase or decrease net income/(loss) in the period such adjustments are made. If our estimates require adjustments, it could have a significant impact on our consolidated financial
statements. </font></p><br /><hr noshade=""/><hr noshade=""/><br /><b>(5) ACQUISITION OF ZYSTOR THERAPEUTICS, INC. </b><p style="margin-top:0px;margin-bottom:-6px"><font size="1"></font></p><p style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">On August17, 2010, the Company acquired all of the
capital stock of ZyStor Therapeutics, Inc. (ZyStor), a privately held biotechnology company, pursuant to a securities purchase agreement dated August17, 2010 between the Company, ZyStor, the holders of outstanding capital stock and rights to
acquire capital stock of ZyStor and the representative of such holders. ZyStor engaged in developing enzyme replacement therapies for the treatment of lysosomal storage disorders. ZyStors lead product candidate, ZC-701, now referred to as
BMN-701, a novel fusion of insulin-like growth factor 2 and alpha glucosidase in development for the treatment of Pompe disease. </font></p><p style="margin-top:0px;margin-bottom:0px"><font size="1"></font></p><p style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">In connection with its acquisition of ZyStor, the Company paid $20.3 million, net of transaction costs, upfront for all of the outstanding
common stock of ZyStor. Additionally at the closing, the Company held back $2.0 million of the purchase price as indemnification against possible claims to pay any unidentified obligations of the former ZyStor stockholders. The Company also agreed
to pay ZyStor stockholders additional consideration in future periods up to $93.0 million (undiscounted) in milestone payments if certain annual sales, cumulative sales and development milestones are met. The fair value of the contingent acquisition
consideration payments on the acquisition date was $15.6 million and was estimated by applying a probability-based income approach utilizing an appropriate discount rate. This estimation was based on significant inputs that are not observable in the
market, referred to as level 3 inputs. Key assumptions includeda discount rate of 5.6% and various probability factors. As of December31, 2010, the range of outcomes and assumptions used to develop these estimates have not changed (see
Note 16 for additional discussion regarding fair value measurements of the contingent acquisition consideration payable). </font></p><p style="margin-top:0px;margin-bottom:0px"><font size="1"></font></p><p align="center" style="margin-top:0px;margin-bottom:0px"><font size="2" style="font-family:Times New Roman">F-16
</font></p><p style="page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/><h5 align="left"><a href="#toc">Table of Contents</a></h5><p align="center" style="margin-top:0px;margin-bottom:0px"><font size="2" style="font-family:Times New Roman"><b>BIOMARIN PHARMACEUTICAL INC. </b></font></p><p style="margin-top:0px;margin-bottom:-6px"><font size="1"></font></p><p align="center" style="margin-top:0px;margin-bottom:0px"><font size="2" style="font-family:Times New Roman"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS(Continued) </b></font></p><p align="center" style="margin-top:0px;margin-bottom:0px"><font size="2" style="font-family:Times New Roman"><b>(In thousands of U.S. dollars, except per share amounts or as otherwise disclosed)
</b></font></p><p style="margin-top:0px;margin-bottom:0px"><font size="1"></font></p><p style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">The following table presents the allocation of the purchase consideration, including the
contingent acquisition consideration payable, based on fair value: </font></p><p style="margin-top:0px;margin-bottom:0px"><font size="1"></font></p><table align="center" border="0" cellpadding="0" cellspacing="0" width="80%">
<tr>
<td width="87%"></td>
<td valign="bottom" width="6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr bgcolor="#cceeff">
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Upfront cash payments</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman">$</font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman"> 20,250</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td></tr>
<tr>
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Present value of cash held back at closing</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">1,890</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td></tr>
<tr bgcolor="#cceeff">
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Contingent acquisition consideration payable</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">15,560</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td></tr>
<tr>
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Transaction costs included in Selling, General&amp; Administrative (SG&amp;A) expense</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">(1,751</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">)</font></td></tr>
<tr style="font-size:1px">
<td valign="bottom"></td>
<td valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td></td></tr>
<tr bgcolor="#cceeff">
<td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Total consideration</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman">$</font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">35,949</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td></tr>
<tr style="font-size:1px">
<td valign="bottom"></td>
<td valign="bottom"></td>
<td style="border-top:3px double #000000" valign="bottom"></td>
<td style="border-top:3px double #000000" valign="bottom"></td>
<td></td></tr>
<tr>
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Cash and cash equivalents</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman">$</font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">13</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td></tr>
<tr bgcolor="#cceeff">
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Other current assets</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">14</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td></tr>
<tr>
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Property, plant and equipment</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">54</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td></tr>
<tr bgcolor="#cceeff">
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Acquired deferred tax assets</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">7,600</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td></tr>
<tr>
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Intangible assetsIn Process Research&amp; Development (IPR&amp;D)</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">27,600</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td></tr>
<tr style="font-size:1px">
<td valign="bottom"></td>
<td valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td></td></tr>
<tr bgcolor="#cceeff">
<td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Total identifiable assets acquired</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman">$</font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">35,281</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td></tr>
<tr style="font-size:1px">
<td valign="bottom"></td>
<td valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td></td></tr>
<tr>
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Accounts payable and accrued expenses</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">(1,644</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">)</font></td></tr>
<tr bgcolor="#cceeff">
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Deferred tax liability</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">(10,692</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">)</font></td></tr>
<tr style="font-size:1px">
<td valign="bottom"></td>
<td valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td></td></tr>
<tr>
<td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Total liabilities assumed</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman">$</font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">(12,336</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">)</font></td></tr>
<tr bgcolor="#cceeff">
<td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Net identifiable assets acquired</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">22,945</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td></tr>
<tr>
<td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Goodwill</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">13,004</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td></tr>
<tr style="font-size:1px">
<td valign="bottom"></td>
<td valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td></td></tr>
<tr bgcolor="#cceeff">
<td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Net assets acquired</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman">$</font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">35,949</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td></tr>
<tr style="font-size:1px">
<td valign="bottom"></td>
<td valign="bottom"></td>
<td style="border-top:3px double #000000" valign="bottom"></td>
<td style="border-top:3px double #000000" valign="bottom"></td>
<td></td></tr></table><br /><hr noshade=""/><hr noshade=""/><br /><b>(6) ACQUISITION OF LEAD THERAPEUTICS, INC. </b><p style="margin-top:0px;margin-bottom:-6px"><font size="1"></font></p><p style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">On February10, 2010, the Company acquired LEAD
Therapeutics, Inc. (LEAD), a small private drug discovery and early stagedevelopment company with a key compound LT-673, now referred to as BMN-673, an orally available poly (ADP-ribose) polymerase(PARP) inhibitor for the treatment of
patients with rare, genetically defined cancers for a total purchase price of $39.1million. </font></p><p style="margin-top:0px;margin-bottom:0px"><font size="1"></font></p><p style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">In connection with its acquisition of LEAD, the Company paid $18.6 million in cash for all of the outstanding common stock of LEAD. The Company also agreed to pay the LEAD stockholders additional
consideration in future periods up to $68.0 million (undiscounted) in milestone payments if certain clinical, development and sales milestones are met. The fair value of the contingent acquisition consideration payments was $20.5 million and was
estimated by applying a probability-based income approach utilizing an appropriate discount rate. This estimation was based on significant inputs that are not observable in the market, referred to as level 3 inputs. Key assumptions included a
discount rate of 6.4% andvarious probability factors. As December31, 2010, the range of outcomes and assumptions used to develop these estimates have not significantly changed (see Note 16 for additional discussion regarding fair value
measurements of the contingent acquisition consideration payable). In December 2010, the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom completed its review of the Companys Clinical Trial Application and
issued a notice of acceptance for BMN-673 resulting in a payment of a regulatory milestone of $11.0 million to the former stockholders. </font></p><br /><hr noshade=""/><hr noshade=""/><br /><b>(7) ACQUISITION OF HUXLEY PHARMACEUTICALS, INC. </b><p style="margin-top:0px;margin-bottom:-6px"><font size="1"></font></p><p style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">On October23, 2009, the Company acquired Huxley
Pharmaceuticals, Inc. (Huxley), which had rights to a proprietary form of 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate, which the Company has branded Firdapse, for the rare autoimmune disease Lambert Eaton Myasthenic Syndrome (LEMS) for a
total purchase price of $37.2 million. As a result of the acquisition, the Company was the first to market an approved treatment for LEMS in Europe. The Company launched Firdapse on a country by county basis in the EU in April 2010. </font></p><p style="margin-top:0px;margin-bottom:0px"><font size="1"></font></p><p style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">In connection with its acquisition of Huxley, the Company
paid $15.0 million upfront for all of the outstanding common stock of Huxley. The Company has also agreed to pay the Huxley stockholders additional consideration in future periods up to $42.9 million (undiscounted) in milestone payments if certain
annual sales, cumulative sales and development milestones are met. The fair value of the contingent acquisition consideration payments on the acquisition date was $22.2 million and was estimated by applying a probability-based income approach
utilizing an appropriate discount rate. This estimation was based on significant inputs that are not observable in the market, referred to as level 3 inputs. Key assumptions includea discount rate of 6.3% and various probability factors. As of
December31, 2010, the range of outcomes and assumptions used to develop these estimates have not significantly changed (see Note 16 for additional discussion regarding fair value </font></p><p style="margin-top:0px;margin-bottom:0px"><font size="1"></font></p><p align="center" style="margin-top:0px;margin-bottom:0px"><font size="2" style="font-family:Times New Roman">F-19
</font></p><p style="page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/><h5 align="left"><a href="#toc">Table of Contents</a></h5><p align="center" style="margin-top:0px;margin-bottom:0px"><font size="2" style="font-family:Times New Roman"><b>BIOMARIN PHARMACEUTICAL INC. </b></font></p><p style="margin-top:0px;margin-bottom:-6px"><font size="1"></font></p><p align="center" style="margin-top:0px;margin-bottom:0px"><font size="2" style="font-family:Times New Roman"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS(Continued) </b></font></p><p align="center" style="margin-top:0px;margin-bottom:0px"><font size="2" style="font-family:Times New Roman"><b>(In thousands of U.S. dollars, except per share amounts or as otherwise disclosed)
</b></font></p><p style="margin-top:0px;margin-bottom:0px"><font size="1"></font></p><p style="margin-top:0px;margin-bottom:0px"><font size="2" style="font-family:Times New Roman">
measurements of the contingent acquisition payable). In November 2009, the U.S. Food and Drug Administration (FDA) granted Firdapse U.S. orphan status, resulting in a payment of $1.0million
to the former Huxley stockholders. In December 2009, the European Medicines Agency (EMEA) granted marketing approval for Firdapse, which resulted in a payment of $6.5 million in the second quarter of 2010 to the former Huxley stockholders.
</font></p><br /><hr noshade=""/><hr noshade=""/><br /><b>Contingent<br/>Acquisition<br/>Payable</b><br/><td valign="bottom"><font size="1"></font></td><tr bgcolor="#cceeff">
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Fair value at December31, 2009</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman">$</font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">21,213</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td></tr><td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Fair value at December31, 2009</font></p></td><p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Fair value at December31, 2009</font></p><td valign="bottom"><font size="1"></font></td><td valign="bottom"><font size="2" style="font-family:Times New Roman">$</font></td><td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">21,213</font></td><td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td><tr>
<td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Contingent acquisition consideration payable resulting from the LEAD acquisition</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">20,456</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td></tr><td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Contingent acquisition consideration payable resulting from the LEAD acquisition</font></p></td><p style="margin-left:3.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Contingent acquisition consideration payable resulting from the LEAD acquisition</font></p><td valign="bottom"><font size="1"></font></td><td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td><td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">20,456</font></td><td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td><tr bgcolor="#cceeff">
<td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Contingent acquisition consideration payable resulting from the ZyStor acquisition</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">15,560</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td></tr><td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Contingent acquisition consideration payable resulting from the ZyStor acquisition</font></p></td><p style="margin-left:3.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Contingent acquisition consideration payable resulting from the ZyStor acquisition</font></p><td valign="bottom"><font size="1"></font></td><td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td><td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">15,560</font></td><td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td><tr>
<td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Change in valuation of contingent acquisition consideration payable to former Huxley stockholders</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">1,155</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td></tr><td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Change in valuation of contingent acquisition consideration payable to former Huxley stockholders</font></p></td><p style="margin-left:3.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Change in valuation of contingent acquisition consideration payable to former Huxley stockholders</font></p><td valign="bottom"><font size="1"></font></td><td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td><td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">1,155</font></td><td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td><tr bgcolor="#cceeff">
<td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Change in valuation of contingent acquisition consideration payable to former LEAD stockholders</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">3,298</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td></tr><td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Change in valuation of contingent acquisition consideration payable to former LEAD stockholders</font></p></td><p style="margin-left:3.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Change in valuation of contingent acquisition consideration payable to former LEAD stockholders</font></p><td valign="bottom"><font size="1"></font></td><td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td><td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">3,298</font></td><td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td><tr>
<td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Change in valuation of contingent acquisition consideration payable to former ZyStor stockholders</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">(464</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">)</font></td></tr><td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Change in valuation of contingent acquisition consideration payable to former ZyStor stockholders</font></p></td><p style="margin-left:3.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Change in valuation of contingent acquisition consideration payable to former ZyStor stockholders</font></p><td valign="bottom"><font size="1"></font></td><td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td><td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">(464</font></td><td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">)</font></td><tr bgcolor="#cceeff">
<td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Payments related to EMEA approval of Firdapse to former Huxley stockholders</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">(6,500</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">)</font></td></tr><td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Payments related to EMEA approval of Firdapse to former Huxley stockholders</font></p></td><p style="margin-left:3.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Payments related to EMEA approval of Firdapse to former Huxley stockholders</font></p><td valign="bottom"><font size="1"></font></td><td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td><td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">(6,500</font></td><td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">)</font></td><tr>
<td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Payments related to the MHRA acceptance of the CTA for BMN-673 to former LEAD stockholders</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">(11,000</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">)</font></td></tr><td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Payments related to the MHRA acceptance of the CTA for BMN-673 to former LEAD stockholders</font></p></td><p style="margin-left:3.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Payments related to the MHRA acceptance of the CTA for BMN-673 to former LEAD stockholders</font></p><td valign="bottom"><font size="1"></font></td><td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td><td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">(11,000</font></td><td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">)</font></td><tr style="font-size:1px">
<td valign="bottom"></td>
<td valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td></td></tr><td valign="bottom"></td><td valign="bottom"></td><td style="border-top:1px solid #000000" valign="bottom"></td><tr bgcolor="#cceeff">
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Fair value at December31, 2010</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman">$</font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">43,718</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td></tr><td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Fair value at December31, 2010</font></p></td><p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Fair value at December31, 2010</font></p><td valign="bottom"><font size="1"></font></td><td valign="bottom"><font size="2" style="font-family:Times New Roman">$</font></td><td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">43,718</font></td><td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td><tr style="font-size:1px">
<td valign="bottom"></td>
<td valign="bottom"></td>
<td style="border-top:3px double #000000" valign="bottom"></td>
<td style="border-top:3px double #000000" valign="bottom"></td>
<td></td></tr><td valign="bottom"></td><td valign="bottom"></td><td style="border-top:3px double #000000" valign="bottom"></td><p style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">As discussed in Notes 5, 6 and
7, the Company acquired intangible assets as a result of the ZyStor, LEAD and Huxley acquisitions. The estimated fair value of these long-lived assets was measured using level 3 inputs. </font></p><p style="margin-top:0px;margin-bottom:0px"><font size="1"></font></p><p style="margin-top:0px;margin-bottom:0px"><font size="2" style="font-family:Times New Roman"><b>(17) STOCKHOLDERS EQUITY </b></font></p>